(4aS)-10c-Formyloxy-2.2.6at.6bc.9.9.12ac-heptamethyl-4ar-formyloxymethyl-(8atH.12btH.14bcH)-Δ14-eicosahydro-picen | 107600-64-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (4aS)-10c-Formyloxy-2.2.6at.6bc.9.9.12ac-heptamethyl-4ar-formyloxymethyl-(8atH.12btH.14bcH)-Δ14-eicosahydro-picen
• 英文别名: (4aS)-10c-Formyloxy-2.2.6at.6bc.9.9.12ac-heptamethyl-4ar-formyloxymethyl-(8atH.12btH.14bcH)-Δ¹⁴-eicosahydro-picen；Oleanen-(12)-diyl-(3β.28)-diformiat；3β.28-Diformyloxy-oleanen-(12)；Di-O-formyl-erythrodiol；Di-O-formyl-erythrodiol (Olean-12-en-3β,28-diol-diformiat)；Erythrodioldiformiat
• CAS: 107600-64-6
• 化学式: C₃₂H₅₀O₄
• 分子量: 498.747
• InChiKey: CLCIXDDMRBFFSA-NEIIXNPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  36.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.6
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  3-软脂酸赤二醇酯 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 (4aS)-10c-Formyloxy-2.2.6at.6bc.9.9.12ac-heptamethyl-4ar-formyloxymethyl-(8atH.12btH.14bcH)-Δ14-eicosahydro-picen
  参考文献：
  名称：

  马杜卡丁香。果肉和树皮的成分

  摘要：

  摘要 除了 α-菠菜甾醇、β-谷甾醇的 β-d-葡萄糖苷、α-和 β-香树脂醇的乙酸酯以及迄今为止未报道的从 Madhuca 的树皮和果肉中分离的 3β-palmitoxy-olea-12en-28-ol butyracea，另外两种酯——齐墩果酸棕榈酸酯和桦木酸棕榈酸酯——分别从果肉和树皮中分离出来。Friedelin 也存在于树皮中。从两种 Madhuca 物种中分离出的化学成分，即 latifolia 和 butyracea，表明除了化学分类学意义之外类似的生物合成途径。

  DOI：

  10.1016/s0031-9422(00)88239-4

文献信息

• Orr et al., Journal of the American Pharmaceutical Association (1912), 1945, vol. 34, p. 39,40
  作者：Orr et al.

  DOI：——

  日期：——
• SOCIOECONOMIC COSTS OF RHEUMATIC DISEASES Implications for Technology Assessment
  作者：Dick Jonsson、Magnus Husberg

  DOI：10.1017/s0266462300103228

  日期：2000.10

  Objectives: To study the socioeconomic impact of rheumatic illness in Sweden and to discuss the consequences for technology assessment studies.Methods: A cost-of-illness study based on data from official statistics and treatment studies.Results: The total socioeconomic cost was 52 billion Swedish kronor (SEK) in 1994. The imbalance between direct (10% of total) and indirect costs (90effectiveness of the healthcare sector, the need for new treatment methods, appropriate information systems, and technology assessment studies as well as the institutional arrangements for rehabilitation and basic medical research.Conclusions: A discussion of solutions for financial cooperation between county councils and regional social insurance offices should be considered. The new biotechnological pharmaceuticals will increase the cost for drugs in health care about 20 times, but the total socioeconomic cost for society may remain at the same level due to a decrease of inpatient costs and indirect costs for loss of production as well as a decrease of transfer payments from social insurance. It is unavoidable that the new pharmaceuticals require priority discussions and active resource allocation in health care and in other sectors of society.